Gene-Editing shot takes aim at rare fat disease
NCT ID NCT07176923
First seen Oct 01, 2025 · Last updated May 02, 2026 · Updated 22 times
Summary
This early-stage study tests a new treatment called CS-121 for people with familial chylomicronemia syndrome (FCS), a rare genetic condition causing extremely high blood fats and risk of pancreatitis. CS-121 uses gene-editing technology delivered via lipid nanoparticles to target a gene called APOC3, aiming to lower triglyceride levels. The study involves 15 adults aged 18-55 and focuses on safety and how well the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.